| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/14/2010 | WO2010005572A2 Alpha-keto heterocycles as faah inhibitors |
| 01/14/2010 | WO2010005558A2 Pi3k isoform selective inhibitors |
| 01/14/2010 | WO2010005528A2 Pyrrolopyridine carboxylic acid derivatives |
| 01/14/2010 | WO2010005438A1 Method of treating migraine using guava |
| 01/14/2010 | WO2010005400A1 Opioid agonist compositions for pain management |
| 01/14/2010 | WO2010005387A1 New method and biomarkers for the diagnosis of multiple sclerosis |
| 01/14/2010 | WO2010005310A2 Complement antagonists and uses thereof |
| 01/14/2010 | WO2010004982A1 Ameliorating or therapeutic agent for dyslipidemia |
| 01/14/2010 | WO2010004837A1 Therapeutic agent for amyotrophic lateral sclerosis |
| 01/14/2010 | WO2010004535A2 Therapeutic methods and compositions employing peptide compounds |
| 01/14/2010 | WO2010004507A1 Thiazolidine compounds as orexin receptor antagonists |
| 01/14/2010 | WO2010004256A1 Controlled release treatment of depression |
| 01/14/2010 | WO2010004221A2 Use of indole derivatives as nurr-1 activators for treating parkinson’s disease |
| 01/14/2010 | WO2010004215A2 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof |
| 01/14/2010 | WO2010004139A1 New cycloalkylated benzothiadiazine derivatives, method for preparing them and pharmaceutical compositions containing them |
| 01/14/2010 | WO2010004003A2 Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction |
| 01/14/2010 | WO2010003976A1 Cyclic sulfones with aminobenzyl substitution useful as bace inhibitors |
| 01/14/2010 | WO2010003760A2 Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity |
| 01/14/2010 | WO2010003287A1 THE USE OF POTASSIUM 2-(α- HYDROXYPENTYL) BENZOATE IN THE MANUFACTURE OF MEDICAMENTS FOR PREVENTING AND/OR TREATING SENILE DEMENTIA |
| 01/14/2010 | WO2009144569A3 Hydrogel capable of containing and conveying cells |
| 01/14/2010 | WO2009143268A3 Treatment of mitochondrial diseases with an erythropoietin mimetic |
| 01/14/2010 | WO2009143156A3 Imidazo [1, 2-a] pyridine compounds as gaba-a receptor modulators |
| 01/14/2010 | WO2009137251A3 Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings |
| 01/14/2010 | WO2009126530A3 Piperidine derivatives as cgrp receptor antagonists |
| 01/14/2010 | WO2009124103A3 Combination therapies comprising par1 antagonists with par4 antagonists |
| 01/14/2010 | WO2009121872A3 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| 01/14/2010 | WO2009120371A3 Computationally designed inhibitors of amyloidosis |
| 01/14/2010 | WO2009080821A3 Multitarget compounds active at a ppar and cannabinoid receptor |
| 01/14/2010 | WO2008133709A3 Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production |
| 01/14/2010 | US20100010097 Methods for treating mild cognitive impairment and alzheimer's disease |
| 01/14/2010 | US20100010090 Ampa receptor potentiators |
| 01/14/2010 | US20100010087 Methods for Inducing Stem Cell Migration and Specialization with EC-18 |
| 01/14/2010 | US20100010079 Proanthocyanidins for the Treatment of Amyloid and Alpha-Synuclein Diseases |
| 01/14/2010 | US20100010070 Use of nucleic acid sequences for the treatment of neuralogical and psychiatric diseases and compositions |
| 01/14/2010 | US20100010061 Cb1 receptor modulators |
| 01/14/2010 | US20100010046 Pharmaceutical formulation for parenteral administration |
| 01/14/2010 | US20100010044 Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide |
| 01/14/2010 | US20100010042 Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| 01/14/2010 | US20100010020 Phosphodiesterase 4 inhibitors |
| 01/14/2010 | US20100010017 Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
| 01/14/2010 | US20100010011 Compounds that act as a vehicle for delivery through the blood-brain barrier and charge delivery vehicle constructions |
| 01/14/2010 | US20100010008 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 01/14/2010 | US20100010004 Inhibitors of histone deacetylase |
| 01/14/2010 | US20100009999 Alkyl substituted indoloquinoxalines |
| 01/14/2010 | US20100009997 Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug |
| 01/14/2010 | US20100009995 Maleate Salts of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-oxo-6,7-dihydro-5H-Pyrrolo[3,4-b]Pyrazine |
| 01/14/2010 | US20100009994 L-Malate Salts of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-Oxo-6,7-Dihydro-5H-Pyrrolo[3,4-b]Pyrazine |
| 01/14/2010 | US20100009988 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| 01/14/2010 | US20100009987 Aminothiazole derivatives as inhibitors of mark |
| 01/14/2010 | US20100009985 THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS |
| 01/14/2010 | US20100009983 5 ht receptor mediated neurogenesis |
| 01/14/2010 | US20100009982 Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof |
| 01/14/2010 | US20100009974 Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them |
| 01/14/2010 | US20100009971 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound |
| 01/14/2010 | US20100009970 Compositions and methods for treatment of viral diseases |
| 01/14/2010 | US20100009965 Cyclic malonamides as inhibitors of abeta protein production |
| 01/14/2010 | US20100009962 Benzyl-substituted quinolone m1 receptor positive allosteric modulators |
| 01/14/2010 | US20100009895 Method for selective localization of active agents at and in mitochondria and corresponding active agents |
| 01/14/2010 | US20100008995 Processes for preparing pharmaceutical compositions |
| 01/14/2010 | US20100008994 Electrospun structures and methods for forming and using same |
| 01/14/2010 | US20100008992 Treatment of disc degenerative disease and compositions for same |
| 01/14/2010 | US20100008990 Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| 01/14/2010 | US20100008986 Pharmaceutical compositions comprising sumatriptan and naproxen |
| 01/14/2010 | US20100008985 Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
| 01/14/2010 | US20100008974 Transdermal granisetron |
| 01/14/2010 | US20100008936 IL-16 antagonist peptides and DNA encoding the peptides |
| 01/14/2010 | US20100008929 Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| 01/14/2010 | US20100008927 Use of (S)-Roscovitine for Prevention and/or Treatment of Neurological Diseases |
| 01/14/2010 | CA2767331A1 Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 01/14/2010 | CA2743975A1 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| 01/14/2010 | CA2730473A1 Novel treatment |
| 01/14/2010 | CA2730377A1 Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
| 01/14/2010 | CA2730302A1 Use of indole derivatives as nurr-1 activators for treating parkinson's disease |
| 01/14/2010 | CA2730271A1 Pi3k isoform selective inhibitors |
| 01/14/2010 | CA2730253A1 Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide |
| 01/14/2010 | CA2730203A1 Complement antagonists and uses thereof |
| 01/14/2010 | CA2730154A1 The application of potassium 2-(1-hydroxypentyl)-benzoate (d1-phpb) for the prevention and treatment of alzheimer's disease |
| 01/14/2010 | CA2730111A1 Synthesis of metabolically stable agents for alcohol and drug abuse |
| 01/14/2010 | CA2730073A1 Method of promoting neurogenesis |
| 01/14/2010 | CA2730003A1 Cyclic sulfones with aminobenzyl substitution useful as bace inhibitors |
| 01/14/2010 | CA2729985A1 Thiazolidine compounds as orexin receptor antagonists |
| 01/14/2010 | CA2729896A1 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof |
| 01/14/2010 | CA2728193A1 Controlled release treatment of depression |
| 01/14/2010 | CA2727146A1 Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity |
| 01/13/2010 | EP2143719A1 Pharmaceutical composition, food or beverage capable of enhancing sympathetic nerve activity |
| 01/13/2010 | EP2143713A1 Novel pyrrolinone derivative and medicinal composition containing the same |
| 01/13/2010 | EP2143434A1 Composition for promoting ketone compound formation |
| 01/13/2010 | EP2143431A1 Protective agent for neurocyte comprising amidino derivative as active ingredient |
| 01/13/2010 | EP2143427A1 Medicinal composition, food or drink having effect of enhancing parasympathetic nervous actions |
| 01/13/2010 | EP2143424A1 Oral pharmaceutical preparation for colon-specific delivery |
| 01/13/2010 | EP2142554A1 Non-basic melanin concentrating hormone receptor-1 antagonists |
| 01/13/2010 | EP2142538A1 Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| 01/13/2010 | EP2142536A1 Aminopyrimidine derivatives as glutaminyl cyclase inhibitors |
| 01/13/2010 | EP2142531A1 Benzimidazole cannabinoid agonists |
| 01/13/2010 | EP2142527A1 Pyridine and pyrimidine derivatives as mglur2 antagonists |
| 01/13/2010 | EP2142515A1 Novel inhibitors |
| 01/13/2010 | EP2142514A1 Thiourea derivatives as glutaminyl cyclase inhibitors |
| 01/13/2010 | EP2142513A1 Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors |
| 01/13/2010 | EP2142511A2 Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments |
| 01/13/2010 | EP2142502A1 Pyrrole and isoindole carboxamide derivatives as p2x7 modulators |